IQ4I Research & Consultancy Published a New Report on "Type 2 Diabetes Pipeline Analysis"
The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies, Gene therapies, Recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations.
Indianapolis, IN, June 11, 2015 --(PR.com)-- Factors contributing to the market growth include, technological advancements leading to emergence of novel therapeutics & mechanisms, increasing incidence of diabetes, obesity & cardiac diseases, alteration in lifestyle and high unmet needs in current treatments options.
IQ4I analysis indicates that 37% of candidates are in Pre-clinical stage followed by 20% in PII clinical
In addition to small molecules, there is growing interest among researchers on large molecules and novel
therapies, such as
o RNA-based therapy
o Stem cell therapy
o Monoclonal antibody-based therapy
o Gene therapy
o Recombinant proteins
Epidemiology of T2D is reviewed to understand potential significance and impact of the disease.
Various T2D associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for diabetes along with disease progression biomarkers associated with T2D.
In market analysis section, global Type 2 Diabetes (T2D) drugs market is indicated region-wise along with the CAGRs forecasted from 2015-2021.
Forecasting model for T2D market
T2D market dynamics
Global and regional T2D drugs market
Cost-burden diabetes care in U.S
Pipeline analysis by developmental stage (Discovery to Marketing).Pipeline analysis by modalities
o Monoclonal Antibodies pipeline analysis
o RNA-therapeutics pipeline analysis
o Stem cell therapy pipeline analysis
o Gene therapy pipeline analysis
o Recombinant protein pipeline analysis
Pipeline analysis by leading players & Target analysis
Drug analysis based on mechanism (alpha-cell secretion, alpha-cell mass decline, kidney protection, insulin sensitizers, Triglyceride lowering, weight loss β-cell mass increase, β-cell mass decline, β-cell protection & β-cell regeneration).
Global key players overview
Global key players Pipeline data (Discovery, Pre-clinical, Clinical & Marketing)
Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)
IQ4I analysis indicates that 37% of candidates are in Pre-clinical stage followed by 20% in PII clinical
In addition to small molecules, there is growing interest among researchers on large molecules and novel
therapies, such as
o RNA-based therapy
o Stem cell therapy
o Monoclonal antibody-based therapy
o Gene therapy
o Recombinant proteins
Epidemiology of T2D is reviewed to understand potential significance and impact of the disease.
Various T2D associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for diabetes along with disease progression biomarkers associated with T2D.
In market analysis section, global Type 2 Diabetes (T2D) drugs market is indicated region-wise along with the CAGRs forecasted from 2015-2021.
Forecasting model for T2D market
T2D market dynamics
Global and regional T2D drugs market
Cost-burden diabetes care in U.S
Pipeline analysis by developmental stage (Discovery to Marketing).Pipeline analysis by modalities
o Monoclonal Antibodies pipeline analysis
o RNA-therapeutics pipeline analysis
o Stem cell therapy pipeline analysis
o Gene therapy pipeline analysis
o Recombinant protein pipeline analysis
Pipeline analysis by leading players & Target analysis
Drug analysis based on mechanism (alpha-cell secretion, alpha-cell mass decline, kidney protection, insulin sensitizers, Triglyceride lowering, weight loss β-cell mass increase, β-cell mass decline, β-cell protection & β-cell regeneration).
Global key players overview
Global key players Pipeline data (Discovery, Pre-clinical, Clinical & Marketing)
Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)
Contact
IQ4I Research & Consultancy Pvt. Ltd.
Satish Birudukota
+91 8060500229
iq4i.com
Satish Birudukota
+91 8060500229
iq4i.com
Contact
Categories